Die 36 Monatsergebnisse sind besser als die 24-Monatsergebnisse:
PSDV and alimera; Turned to be better than what FDA thought! PSDV $4.36 now!
"Hidden Stocks for High Returns
By Rich Duprey |
Like the song says, investors are looking for stocks to love in all the wrong places. They'll pile into the momentum stocks everyone else buys but ignore lesser-known opportunities for fear of straying from the crowd.
Yet the search for undiscovered jewels has informed many of our Motley Fool Hidden Gems picks, from Dawson Geophysical to Sotheby's. Overlooked by Wall Street and Main Street, and thus undervalued, these stocks hold the best potential to deliver outsized returns.
The Motley Fool CAPS community knows a bargain when it sees one. Below, you'll find several under-the-radar stocks that brim with promise. These companies have garnered 100 or less active recommendations on CAPS, though the community thinks they still have outsized potential.
Stock
CAPS Rating
(out of 5)
# of Active Picks
Est. EPS Growth
Next Year
Alimera Sciences (Nasdaq: ALIM )
Naturally, we want you to look a bit closer at these stocks before buying. Maybe investors are staying away from these stocks for a reason, so make sure there's nothing seriously wrong with the company before you plug it into your own portfolio.
Blinded by the light
Last December, the Food and Drug Administration gave Alimera Sciences a poke in the eye by issuing a complete response letter for its diabetic macular edema treatment Iluvien. Although they didn't outright reject the therapy, they wanted more data on its efficacy from patients receiving longer term care as well as on its third-party partner manufacturing processes. Not only did Alimera get blindsided, but its partner pSivida (Nasdaq: PSDV ) did, too.
The three-year results for Iluvien from two late-stage studies were reported last month, and it showed the therapy was better than the standard care by a statistically significant amount. Alimera plans on filing its response to the FDA during the second quarter and points out the review period could be upward of six months away. In the meantime, investors will have to bide their time and wonder whether the growth of cataracts in patients will derail approval. Some 80% of patients who had not undergone cataract surgery prior to entering the trial ultimately went under the knife by the end of the 36-month trial period."
source ; motley fool |
Thread abonnieren
